Following on from information provided to NICE by the company in May 2017, the appraisal of Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 746

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors Sunesis
Others Department of Health
  NHS England
  NHS Somerset CCG
  NHS South Eastern Hampshire CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer52
  Delete Blood Cancer
  Equalities National Council
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie Cancer Care
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
  UK Chronic Lymphocytic Leukaemia Forum
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  Cancer Research UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiography
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord (cytarabine, filgrastim )
  Actavis (fludarabine)
  Amgen (filgrastim)
  Hospira UK (cytarabine, fludarabine, filgrastim )
  Napp Pharmaceuticals (cytarabine)
  Pfizer (cytarabine, idarubicin)
  Sandoz (fludarabine, filgrastim)
  Teva (fludarabine)
General commentators Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Blood and Transplant
  NHS Commercial Medicines Unit
  NHS Confederation
  Scottish Medicines Consortium
Relevant research groups Bloodwise
  Cochrane Haematological Malignancies Group
  Institute of Cancer Research
  Leuka
  Leukaemia Busters
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 November 2022 Discontinued. Following on from information provided to NICE by the company in May 2017, the appraisal of Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
19 April 2017 Suspended. The Department of Health has asked NICE to conduct a Single Technology Appraisal of vosaroxin within its marketing authorisation for treating relapsed or refractory acute myeloid leukaemia. Following on from advice received from the company, NICE has decided to currently suspend this appraisal on its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties when the situation changes.
14 February 2017 Invitation to participate
09 November 2016 Sunesis was unable to make a submission to NICE ahead of the marketing authorisation for Vosaroxin based on resource constraints and intends to follow up with a full submission in a timely manner. NICE therefore rescheduled this appraisal.
02 June 2016 Draft scope documents
13 May 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual